Abstract
Estrogen Receptor (ER) status is a critical biomarker in breast cancer diagnosis, prognosis, and treatment selection. Recent advances in high-throughput sequencing technologies have enabled the generation of multi-omics datasets that provide complementary molecular information for computational prediction tasks. This study presents a systematic benchmarking analysis of classical machine learning models for ER status prediction using transcriptomic (RNA expression), genomic (copy number variation; CNV), and proteomic (RPPA) data from the TCGA-BRCA cohort.
Methods
A rigorous experimental framework incorporating stratified train-test splitting, stratified five-fold cross-validation, class imbalance handling, and fold-specific feature selection was employed to ensure reliable evaluation and prevent data leakage. Random Forest, XGBoost, LightGBM, CatBoost, Support Vector Machines (SVM), and Logistic Regression were evaluated across single-omic and multi-omic settings.
Results
Results demonstrated that RNA expression provided the strongest predictive signal, while multi-omic integration yielded modest but consistent improvements over individual modalities. Among all evaluated approaches, Random Forest achieved the best overall performance in the integrated multi-omic setting, obtaining a balanced accuracy of 90.3% and an ROC-AUC of 97.1%. Furthermore, recurrent selection of biologically relevant genes, including ESR1, PGR, FOXA1, and GATA3, supported the biological validity of the learned models. These findings indicate that carefully regularized classical machine learning methods remain highly effective for small, high-dimensional genomic datasets and that multi-omic integration provides complementary information for breast cancer ER status prediction.
Blogger's Review: This article highlights the significance of multi-omics data in breast cancer prediction through systematic benchmarking, emphasizing the effectiveness of classical machine learning algorithms in handling high-dimensional data, particularly the outstanding performance of Random Forest, which warrants further exploration in clinical applications.